baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Ascendis Pharma A/S/ US04351P1012 /

2024-04-25 4:38:43 PM	Chg. -5.25	Volume	Bid-	Ask-	High	Low
137.90USD	-3.66%	2,344 Turnover: 325,266.09	-Bid Size: -	-Ask Size: -	140.84	137.43

GlobeNewswire 04-24 United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment o...

GlobeNewswire 04-16 Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.

GlobeNewswire 03-04 Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024

GlobeNewswire 02-15 Royalty Pharma Reports Q4 and Full Year 2023 Results

GlobeNewswire 02-07 Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results

GlobeNewswire 01-31 Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7...

GlobeNewswire 01-31 Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for ...

GlobeNewswire 01-29 New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitm...

GlobeNewswire 01-09 Er-Kim Announces Exclusive Distribution Agreement with Ascendis Pharma A/S to Commercialize 3 Endocr...

GlobeNewswire 01-08 Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (...

GlobeNewswire 01-07 Ascendis Pharma Introduces Vision 2030

GlobeNewswire 01-04 Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer

GlobeNewswire 2023-12-28 Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 2023-12-20 Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated...

GlobeNewswire 2023-12-19 TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Ph...

GlobeNewswire 2023-12-11 FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with...

GlobeNewswire 2023-11-29 Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan

GlobeNewswire 2023-11-20 Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the T...

GlobeNewswire 2023-11-15 Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDA

GlobeNewswire 2023-11-14 BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire 2023-11-08 Royalty Pharma Reports Third Quarter 2023 Results

GlobeNewswire 2023-11-07 Ascendis Pharma Reports Third Quarter 2023 Financial Results

GlobeNewswire 2023-10-31 Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubm...

GlobeNewswire 2023-10-26 Ascendis Presents Updated and New TransCon™ IL-2 β⁄γ Monotherapy and Combination Therapy Data Confir...

GlobeNewswire 2023-10-18 BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

Ascendis Pharma A/S/ US04351P1012 /

If you wish to receive reply to your feedback, please provide your email address.